PRECIGEN, INC. Operating Lease Liability
PRECIGEN, INC. (PGEN) had Operating Lease Liability of $4.46 million as of 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Balance Sheet › Liabilities
us-gaap:OperatingLeaseLiability · last filed 2026-08-04
- 2026-06-30: Operating Lease, Liability $4.46M.
- 2026-03-31: Operating Lease, Liability $4.73M.
- 2025-12-31: Operating Lease, Liability $5.12M.
- 2025-09-30: Operating Lease, Liability $5.30M.
| Period end | Operating Lease, Liability |
|---|---|
| 2026-06-30 | $4.46M 10-Q · filed 2026-08-04 |
| 2026-03-31 | $4.73M 10-Q · filed 2026-05-13 |
| 2025-12-31 | $5.12M 10-K · filed 2026-03-25 |
| 2025-09-30 | $5.30M 10-Q · filed 2025-11-13 |
| 2025-06-30 | $5.15M 10-Q · filed 2025-08-12 |
| 2025-03-31 | $5.42M 10-Q · filed 2025-05-14 |
| 2024-12-31 | $5.50M 10-K · filed 2025-03-19 |
| 2024-09-30 | $5.75M 10-Q · filed 2024-11-14 |
| 2024-06-30 | $6.34M 10-Q · filed 2024-08-14 |
| 2024-03-31 | $6.71M 10-Q · filed 2024-05-14 |
| 2023-12-31 | $7.10M 10-K · filed 2024-03-19 |
| 2023-09-30 | $7.39M 10-Q · filed 2023-11-09 |
| 2023-06-30 | $7.97M 10-Q · filed 2023-08-09 |
| 2023-03-31 | $7.87M 10-Q · filed 2023-05-10 |
| 2022-12-31 | $8.20M 10-K · filed 2023-03-06 |
| 2022-09-30 | $8.98M 10-Q · filed 2022-11-09 |
| 2022-06-30 | $9.13M 10-Q · filed 2022-08-08 |
| 2022-03-31 | $11.10M 10-Q · filed 2022-05-09 |
| 2021-12-31 | $11.05M 10-K · filed 2022-03-01 |
| 2021-09-30 | $13.16M 10-Q · filed 2021-11-08 |
| 2021-06-30 | $13.76M 10-Q · filed 2021-08-09 |
| 2021-03-31 | $9.60M 10-Q · filed 2021-05-10 |
| 2020-12-31 | $10.40M 10-K · filed 2021-03-01 |
| 2020-09-30 | $24.91M 10-Q · filed 2020-11-09 |
| 2020-06-30 | $25.73M 10-Q · filed 2020-08-10 |
| 2020-03-31 | $26.72M 10-Q · filed 2020-05-11 |
| 2019-12-31 | $28.03M 10-K · filed 2020-03-02 |
| 2019-09-30 | $44.41M 10-Q · filed 2019-11-12 |
| 2019-06-30 | $43.57M 10-Q · filed 2019-08-09 |
| 2019-03-31 | $44.96M 10-Q · filed 2019-05-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NewAmsterdam Pharma Co N.V. (NAMS) | $2.719B | -15.37 | |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| Dyne Therapeutics, Inc. (DYN) | United States | $3.084B | -7.09 |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |